Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics (Nasdaq: OTLK) will report its third quarter fiscal year 2026 financial results and host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. The call will be led by CEO Bob Jahr and EVP/CFO Lawrence A. Kenyon. Domestic participants can dial 877-407-8291, international participants can dial +1 201-689-8345, referencing the Outlook Therapeutics conference call. A live webcast and 90-day archive will be available on the Events page in the Investor section of the company’s website, outlooktherapeutics.com.
Outlook Therapeutics (Nasdaq: OTLK) announced U.S. FDA approval of LYTENAVA™ (bevacizumab-vikg) as the first and only FDA-approved ophthalmic bevacizumab for treating neovascular age-related macular degeneration (wet AMD) in the United States. The ophthalmic formulation is developed specifically for intravitreal use in the eye and is supported by clinical evidence, validated manufacturing, approved labeling, and ongoing FDA oversight.
According to Outlook Therapeutics, the company anticipates 12 years of Reference Product Exclusivity under the BPCIA and is executing a U.S. commercial launch targeting the approximately $8.5 billion anti-VEGF retina market. LYTENAVA is expected to be available to eligible U.S. patients before year-end, with reimbursement and patient-assistance programs to support access. The product already holds marketing authorizations in the EU and UK for wet AMD.
Outlook Therapeutics (Nasdaq: OTLK) announced FDA acceptance of its resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (wet AMD).
The resubmission is under a Class 1 review with a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026. Outlook Therapeutics has begun pre-launch activities while the FDA review proceeds.
Outlook Therapeutics (Nasdaq: OTLK) resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs concluded substantial evidence of effectiveness and indicated no additional trials are required.
The resubmission is designated a Class 1 review, with a PDUFA decision expected within 60 days of FDA receipt, and interactions now focusing on final product labeling.
Outlook Therapeutics (Nasdaq: OTLK) priced a registered direct offering of 8,539,709 common shares at $0.5855 per share, to largest stockholder GMS Ventures and Investments, for expected gross proceeds of $5.0 million.
Closing is expected around May 29, 2026. Warrants for up to 15,488,570 shares will have their exercise price reduced to $0.5855 per share, effective at closing. Net proceeds will support working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) announced that the FDA’s Office of New Drugs has granted its appeal in the Formal Dispute Resolution process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD).
The FDA concluded that substantial evidence of effectiveness has been established based on NORSE TWO plus confirmatory data, enabling Outlook Therapeutics to plan a Class 1 BLA resubmission in June 2026, with a PDUFA decision expected within 60 days of FDA receipt. If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic bevacizumab formulation.
Outlook Therapeutics (Nasdaq: OTLK) reported Q2 FY2026 results and corporate updates. Net loss attributable to common stockholders was $4.5 million, or $0.05 per share, versus $46.4 million, or $1.50, a year earlier. Adjusted net loss was $14.1 million versus $12.4 million.
The company advanced LYTENAVA™ commercialization in Europe, signed a Swiss distribution deal with Mediconsult AG targeting a 2027 launch, and started a real-world evidence study in Germany. An FDA formal dispute resolution decision on ONS-5010/LYTENAVA™ is expected in May 2026. Cash was $7.7 million as of March 31, 2026.
Outlook Therapeutics (Nasdaq: OTLK) closed a registered direct offering of 16,129,033 common shares at $0.31 per share, generating approximately $5.0 million gross proceeds. The company concurrently issued unregistered warrants for up to 16,129,033 shares at a $0.31 exercise price, potentially raising an additional $5.0 million if exercised. The company amended existing warrants (2,142,854 shares) to a $0.31 exercise price; warrants’ exercisability and resale depend on stockholder approval and charter amendment timing. Net proceeds will be used primarily for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) announced a registered direct offering of 16,129,033 shares (or pre-funded warrants) at $0.31 per share and concurrent private-placement unregistered warrants to purchase up to 16,129,033 shares.
The offering is expected to close on or about April 23, 2026, raising approximately $5.0 million gross, with potential additional gross proceeds of about $5.0 million if the unregistered warrants are fully exercised. Proceeds are intended for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) completed a Federal Dispute Resolution meeting with the FDA concerning its ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application for neovascular age-related macular degeneration. A formal FDA response is expected in May 2026. The company said it will update investors after receiving the official feedback.